The BA.3.2 variant, a heavily mutated new COVID-19 strain which may be better able to escape immunity from vaccines or prior infection, is now spreading in the United States and could become the UK's primary variant, according to multiple reports. This 'hyper-mutated' strain is being closely tracked by public health officials due to its approximately 75 genetic mutations in the spike protein, a feature that may make it adept at bypassing the body's immune system. According to reports, the variant's slew of genetic changes in its spike protein sets it apart from other circulating variants, with BA.3.2 potentially able to evade a lot of the immunity already in the population. The variant belongs to the Omicron family but has more mutations than some earlier variants, and it could be significantly more adept at sidestepping immune defenses, including from 2025-2026 COVID vaccines.
Geographically, BA.3.2 has been detected in nearly 23 countries as of last month, with its first appearance in South Africa in November 2024. It was first detected in the U.S. on June 27, 2025, at San Francisco International Airport from a traveler returning from the Netherlands, and as of February, it has been detected in at least 25 states, according to the U.S. Centers for Disease Control and Prevention. According to reports, BA.3.2 spent its first years 'underground' before re-emerging as a potential major variant, with the strain slowly simmering until last fall when it started ramping up in several countries, including the U.S. In Europe, BA.3.2 reached roughly 30 percent of cases in Denmark, Germany, and the Netherlands last fall, and it has been detected in Sweden in a limited number of patient samples and wastewater since winter. As of mid-March 2026, BA.3.2 accounts for about half a percent of recent virus sequences in the U.S., indicating a gradual but persistent presence.
Scientifically, BA.3.2 is a descendent of BA.3, an Omicron subvariant that emerged in 2022, according to the CDC, and it represents a new lineage that's 'genetically distinct' from recent variants. In December 2025, the World Health Organization classified BA.3.2 as a 'variant under monitoring,' reflecting ongoing scrutiny of its potential impact. The variant was nicknamed 'Cicada' by T. Ryan Gregory, Ph.D., a professor at the University of Guelph, drawing a parallel to the insect's periodic emergence. According to reports, BA.3.2 has 70–75 mutations in its spike protein, which set it apart from JN.1 and LP.8.1, the strains targeted by current COVID-19 vaccines, highlighting its unique genetic profile.
Current understanding of BA.3.2's severity and clinical outcomes suggests no major differences from other variants, with no data indicating increased severity, hospitalizations, or deaths associated with BA.3.2, according to WHO. In parts of Europe, BA.3.2 rose to a substantial share of sequenced cases without worse clinical outcomes, and Swedish health authorities assess that it does not pose an increased risk of severe disease compared to other circulating variants. The variant is biologically similar to other Omicron subvariants with no major differences reported, and symptoms of BA.3.2 are similar to those of other respiratory infections. There is not yet evidence that BA.3.2 is more severe than other recent variants, reinforcing a pattern of reduced severity in newer strains.
Vaccine effectiveness and immune evasion concerns persist, as BA.3.2's mutations have the potential to reduce protection from prior COVID infection or vaccination, according to a new study in the CDC's Morbidity and Mortality Weekly Report. However, current vaccines are expected to continue providing protection against severe COVID-19 from BA.3.2, according to multiple reports, suggesting that while infection risk may rise, severe outcomes could be mitigated. According to reports, while future variants may evade immunity, they will probably have a similar not-as-harmful impact on people with some immunity, aligning with this assessment. The exact effectiveness of current vaccines specifically against BA.3.2 infection, beyond severe disease, remains an open question, adding uncertainty to public health planning.
Contradictory evidence exists on BA.3.2's spread dynamics, with some reports indicating it spreads more rapidly than previous strains and may become the UK's primary variant, while the WHO states it has not shown a sustained growth advantage over other co-circulating variants. This disagreement affects the perceived threat level and urgency of public health response, requiring readers to weigh media claims of rapid spread against official data suggesting limited competitive advantage. Additionally, two lab studies found BA.3.2 does not bind as well to human cells as other variants, which may hold it back from spreading faster, according to multiple reports, complicating predictions about its trajectory. The true growth rate and transmissibility of BA.3.2 compared to other circulating variants is thus a key unknown, with conflicting signals from different sources.
The broader COVID-19 context shows the latest wave of infections is beginning to subside in the United States, with health officials and some experts focusing on signs the Omicron variant is fading quickly in communities where it first spread. According to reports, across the United States, there's still states that are probably in the thick of this, with another week or two until they peak, while the trajectory in the U.S. is encouraging but cautioned against declaring premature victory. Within weeks, most of the country could be past the peak of the current surge, according to multiple reports, and the virus may be under control by spring but warned there is no guarantee it will remain that way. Meanwhile, other variants like BA.2 continue to circulate, with two cases detected in Washington State, according to state health officials, and the WHO reporting it has spread to more than 40 countries, though public health officials are still monitoring how infectious BA.2 is and how effectively it evades immunity. So far, there is no indication BA.2 represents a greater threat than the original Omicron strain, and in Denmark, it accounts for 65% of new cases but hospitalizations are still declining because it does not appear to cause more severe illness.
Potential impacts on children and specific populations include that BA.3.2 may spread most effectively among children with no prior immunity, according to multiple reports, raising concerns about transmission in schools and daycare settings. This aligns with patterns seen in earlier variants, where lower immunity levels in younger populations facilitated spread, though severity in children has typically been lower. Public health agencies may need to consider targeted measures if this trend is confirmed, though no specific recommendations have been issued yet.
Public health monitoring and response are ongoing, with experts noting that as long as the virus is circulating globally, the threat of additional variants evolving will continue. The head of the World Health Organization warned the end of the pandemic might not be as near as some believe, and a coordinated global effort may be needed to reduce future variant risks. According to the WHO Director-General, it is dangerous to assume that omicron will be the last variant or that we’re in the endgame, and globally, conditions are ideal for more variants to emerge. This underscores the need for sustained vigilance and international cooperation in tracking and responding to new strains like BA.3.2.
Key unknowns and unanswered questions about BA.3.2 include the exact number of countries where it has been detected, as sources report 'nearly 23' but no precise count, and whether there are any specific symptoms or clinical features unique to BA.3.2 infection. Additionally, what public health measures, if any, are being recommended or implemented in response to BA.3.2's spread remains unclear, with health agencies likely assessing data before issuing guidance. According to reports, given how viruses typically evolve, new variants are likely to cause more mild symptoms, even if more transmissible, suggesting a possible trajectory for BA.3.2, but further research is needed to confirm this.